These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15500381)

  • 21. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
    Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ibandronate: keep life in motion].
    Longo F; Mansueto G
    Tumori; 2004; 90(2):9-16. PubMed ID: 15237599
    [No Abstract]   [Full Text] [Related]  

  • 23. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibandronate in benign bone disease.
    Winzenberg T; Jones G
    Rev Recent Clin Trials; 2008 May; 3(2):139-49. PubMed ID: 18474025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient management issues in metastatic bone disease.
    Cameron D
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):79-82. PubMed ID: 15490381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibandronate reduces skeletal morbidity in patients with breast cancer.
    Tripathy A D; Diel I; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
    McCormack PL; Plosker GL
    Drugs; 2006; 66(5):711-28. PubMed ID: 16620148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Clemons M; Dranitsaris G; Ooi W; Cole DE
    Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.
    Syrigos KN; Michalaki V; Mitromaras A; Pliarchopoulou F; Katirtzoglou N; Antonaki E; Roussou P
    In Vivo; 2002; 16(5):361-3. PubMed ID: 12494878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
    Mystakidou K; Stathopoulou E; Parpa E; Kouloulias V; Kouskouni E; Vlahos L
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1303-10. PubMed ID: 18504612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibandronate in metastatic bone disease: a review of preclinical data.
    Bauss F; Body JJ
    Anticancer Drugs; 2005 Feb; 16(2):107-18. PubMed ID: 15655407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
    Hoskin P; Sundar S; Reczko K; Forsyth S; Mithal N; Sizer B; Bloomfield D; Upadhyay S; Wilson P; Kirkwood A; Stratford M; Jitlal M; Hackshaw A
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26242893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
    Michigami T; Hiraga T; Williams PJ; Niewolna M; Nishimura R; Mundy GR; Yoneda T
    Breast Cancer Res Treat; 2002 Oct; 75(3):249-58. PubMed ID: 12353814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.